News • Advanced materials

Nanocarriers open up to cancer

Nanomaterials that respond to cancer-specific stimuli show potential in the targeted delivery of treatments and imaging compounds, but many challenges remain.

Nanosystems that deliver anticancer drugs or imaging materials to tumours are showing significant progress, particularly those that respond to tumour-related stimuli, according to a review published in the journal Science and Technology of Advanced Materials. However, further research is still required to make sure these delivery systems are stable, non-toxic and biodegradable. Nanocarriers designed to release their contents only in cancerous tissue are of great interest because they can reduce the negative effects of chemotherapeutic agents on healthy tissues. They can also deliver contrast materials to the tumour for enhanced imaging. Nanomaterials are being designed to specifically target tumours by responding to unique tumour conditions, such as acidity and over-expressed enzymes, explain the reviewers from Xiamen University in China.

Researchers are investigating a range of nanomaterials that respond to...
Researchers are investigating a range of nanomaterials that respond to cancer-specific stimuli for delivering imaging compounds and treatments specifically to cancer cells, such as protease-sensitive nanomaterials.

Copyright: ACS Ind. Eng. Chem. Res. 2017, 56, 20, 5761-5777

Acidity levels normally vary between tissue types, and tumours are usually more acidic than the surrounding healthy tissue. Researchers are using this to design delivery vehicles from organic, inorganic and hybrid nanomaterials that release their contents in response to tumours' acidic environment. For example, acid-sensitive polymers have been explored for delivering the chemotherapeutic drug doxorubicin coupled with a fluorescent compound. When the system reaches its target, it is taken up by tumour cells and is exposed to their acidic environment. The polymer then changes its shape in a way that releases its contents, allowing both the treatment and imaging of the cancerous cells.

Reduction potential is also being used as a stimulus for cancer-targeting delivery vehicles. Reduction potential is the measure of the tendency of molecules to acquire electrons and thus become 'reduced'. Reduction potential is different in cancerous tissue than it is in healthy tissue. Nanocarriers are being designed that break down when exposed to a reducing agent in the body called reduced state glutathione tripeptide, which is 1,000 times higher inside tumour cells than outside. This type of nanocarrier has excellent stability in the blood and rapidly responds to the reducing environment in tumours. Some have already been approved by the U.S. Food and Drug Administration for use in clinics.

Considering the promising potential of stimuli-responsive nanomaterial, much more efforts should be made to fabricate more platforms for triggered drug delivery with increased efficiency and reduced side effects for cancer therapy

Other nanocarriers respond to enzymes that are abnormally expressed inside tumours. They are made of materials that these enzymes can break down, thus releasing the contents. The breakdown of the nanocarrier wall can be so effective in some cases, it might reduce the amount of drug needed to have a therapeutic effect.

Despite the promise these nanomaterials show, more work is needed. Acid-responsive carriers, for example, need to have a better drug-loading capacity, stability, and biodegradability. Further examination of the toxicity of enzyme-responsive materials is also required. "Considering the promising potential of stimuli-responsive nanomaterial, much more efforts should be made to fabricate more platforms for triggered drug delivery with increased efficiency and reduced side effects for cancer therapy," the researchers conclude.


Source: Xiamen University/JCN Newswire

30.10.2018

Read all latest stories

Related articles

Photo

News • Cancer research

Black nanoparticles slow tumor growth

Melanin protects our skin from the sun’s damaging rays by absorbing light energy and converting it to heat. This could make it a very effective tool in tumor diagnosis and treatment, as…

Photo

News • From nanotechnology

A better prognostic tool for brain cancer

A new nano-fabricated platform for observing brain cancer cells provides a much more detailed look at how the cells migrate and a more accurate post-surgery prognosis for brain cancer (glioblastoma)…

Photo

Article • Cancer diagnostics II

New nanoparticle could enhance MRI scanning

Scientists in the UK have designed a new self-assembling nano­particle that targets tumours and could lead to quicker diagnosis of cancer. Researchers at Imperial College London report that a new…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Shimadzu – MALDImini-1

Research Use Only

Shimadzu – MALDImini-1

Shimadzu Europa GmbH
Subscribe to Newsletter